China SXT Ownership
| SXTC Stock | USD 2.81 0.18 6.84% |
China |
China Stock Ownership Analysis
The company has price-to-book ratio of 0.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. China SXT Pharmaceuticals recorded a loss per share of 28.58. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of October 2023. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets in China. The company was founded in 2005 and is headquartered in Taizhou, China. China Sxt operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 88 people. To find out more about China SXT Pharmaceuticals contact Feng Zhou at 86 523 8629 8290 or learn more at https://www.sxtchina.com.Besides selling stocks to institutional investors, China SXT also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different China SXT's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align China SXT's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
China SXT Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of China SXT Pharmaceuticals are currently held by insiders. Unlike China SXT's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against China SXT's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of China SXT's insider trades
China Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as China SXT is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading China SXT Pharmaceuticals backward and forwards among themselves. China SXT's institutional investor refers to the entity that pools money to purchase China SXT's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of Montreal | 2024-12-31 | 10 K | Bmo Capital Markets Corp. | 2024-12-31 | 10 K | Ubs Group Ag | 2024-12-31 | 8.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Gsa Capital Partners Llp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Baader Bank Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
China SXT Outstanding Bonds
China SXT issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. China SXT Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most China bonds can be classified according to their maturity, which is the date when China SXT Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
China SXT Corporate Filings
6K | 19th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 21st of January 2025 Other Reports | ViewVerify | |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (28.58) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.